The Potential Role of Dyslipidemia in COVID-19 Severity: an Umbrella Review of Systematic Reviews

The recent coronavirus disease 2019 (COVID-19) outbreak has spread rapidly and has affected the world for almost a year, causing immense economic and social difficulties. Despite efforts to develop vaccines and new treatments, preventing COVID-19 remains challenging and no clear treatment options exist. As of September 11, 2020, roughly 28 million people worldwide have been infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, and more than 900,000 people have died. With some exceptions, most deaths are thought to be related to underlying comorbidities.1 Therefore, identifying the risk factors related to severe COVID-19 is important to enable stratification of risk in advance, to optimize the reallocation of medical resources, and to improve patients' overall prognoses.

As SARS-CoV-2 primarily attacks the respiratory tract, several studies have investigated the relationship between chronic obstructive pulmonary disease,2 asthma,3 or smoking,4 and the severity of COVID-19. However, it has also been found that patients with underlying cardiovascular disease or cardiovascular disease risk factors have a high risk of a severe course of illness or mortality due to COVID-19.5, 6, 7 COVID-19 can also have various cardiovascular manifestations such as myocardial injury, arrhythmias, acute coronary syndrome, and venous thromboembolism.8 Several observational studies and meta-analyses have shown that underlying cardiovascular disease, diabetes mellitus, and hypertension clearly increase the severity and mortality of COVID-19.9, 10, 11 However, unlike diabetes and hypertension, relatively few studies have been conducted on dyslipidemia, one of the most important risk factors of cardiovascular disease. Several observational studies have reported an association between high-density lipoprotein (HDL) cholesterol levels and the severity of COVID-1912, 13; however, the results are inconsistent.

To date, multiple systematic reviews and meta-analyses have been published analyzing the potential link between presence of dyslipidemia and the severity of COVID-19. However, to our knowledge, no attempt has been made to summarize the evidence from these systematic reviews. Therefore, systematically and comprehensively re-evaluated the evidence to provide an overview of the association between dyslipidemia and COVID-19 severity. Specifically, we conducted an umbrella review to evaluate the findings of systematic reviews and/or meta-analyses that investigated the relationship of dyslipidemia and severity of COVID-19 infection and to assess the evidence regarding potential limitations and the consistency of findings.

An umbrella review was performed in this study. An umbrella review provides a summary of existing published meta-analyses and systematic reviews and determines whether authors addressing similar review questions have independently reported similar results and arrived at similar conclusions.14 We applied the Cochrane Collaboration methodology15 and available methodological guidelines for overviews of reviews.16, 17 The study protocol was prospectively registered in the International Prospective Register of Systematic Reviews (PROSPERO Identifier: CRD42020205979).

4. Quality assessment

Two authors (G.J.C. and H.M.K.) independently evaluated the methodological quality of the included studies using the A MeaSurement Tool to Assess systematic Reviews (AMSTAR 2) tool.18 Inconsistencies were resolved through a discussion with a third author (H.K.). AMSTAR 2 is a reliable, valid and critical assessment tool developed from the initial AMSTAR in 2017.18, 19, 20 It contains 16 checklists (7 critical checklists and 9 non-critical checklists) for assessing systematic reviews and meta-analyses, including randomized controlled trials, observational studies on exposure, or both (Table 1). The rating criteria of AMSTAR 2 are as follows: the presence of 0–1 non-critical weakness is defined as high quality; more than 1 non-critical weakness is defined as moderate quality; 1 critical flaw with or without non-critical weaknesses is defined as low quality; and the presence of more than 1 critical flaw with or without non-critical weaknesses is defined as critically low quality. The author responsible for the methodology of this study (H.K.) completed the online AMSTAR 2 checklist available on the AMSTAR website (https://amstar.ca/Amstar_Checklist.php) and a final categorization of each systematic review was generated to classify them as high, moderate, low, or critically low quality.

Table 1
Checklists for assessing systematic reviews and meta-analyses according to the AMSTAR 2 tool

• Click for larger image
• Click for full table
• Download as Excel file

Considerable evidence has been amassed that a history of cardiovascular disease or cardiovascular risk factors such as hypertension and diabetes is closely related to COVID-19 infection and severity.5, 6, 11 Since dyslipidemia is one of the most important cardiovascular risk factors, dyslipidemia is also likely to be closely related to COVID-19. However, research on the role of dyslipidemia in the risk and severity of COVID-19 is relatively lacking. One cause may be that the definition of dyslipidemia itself is rather complicated, unlike diabetes mellitus, hypertension, and obesity. Furthermore, numerous reports have stated that rapid changes in the lipid profile appear to occur in response to COVID-19 infection and the progression of the disease.46 Therefore, there may be a major difference between defining the presence of dyslipidemia before being diagnosed with COVID-19, and defining dyslipidemia at the time of hospitalization after a patient is diagnosed with COVID-19.

In the meta-analysis conducted by Hariyanto and Kurniawan,38 7 observational studies were analyzed.45, 47, 48, 49, 50, 51, 52 In each study, dyslipidemia or hyperlipidemia was defined according to patients' history based on electronic medical records regardless of additional laboratory testing or the use of lipid-lowering drugs. Four of the 7 studies were conducted in China, and 1 study each from the US, France, and Korea was included. The prevalence of dyslipidemia in these studies differed dramatically. In particular, in the studies conducted in China, Hong Kong, and Korea,47, 48, 50, 51, 52 the prevalence of dyslipidemia was much lower than that in the other studies (1%–10%). In the US study,45 the number of patients with dyslipidemia was 1,714, with a prevalence of 32.5%, and in the French study,49 34 patients had dyslipidemia, with a prevalence of 28%. Since there were no overlapping studies in each systematic review included in this umbrella review, we performed a new meta-analysis to analyze the relationship between dyslipidemia and the severity of COVID-19 quantitatively. However, of the 3 studies included in the review of Zaki et al.,39 only 1 study41 described the presence of underlying dyslipidemia. In our new meta-analysis of a total of 8 studies, combining the 7 studies45, 47, 48, 49, 50, 51, 52 included in the study of Hariyanto and Kurniawan38 and the single study41 included in the review of Zaki et al.,39 the relationship between dyslipidemia and severe COVID-19 was confirmed. However, a relevant limitation may be that all studies included in the 2 systematic analyses could not be analyzed. Nevertheless, given the results so far, the prognosis of COVID-19 seems poor in patients with dyslipidemia, so dyslipidemia should be regarded as another important factor in risk stratification models for COVID-19. Prior to the COVID-19 pandemic, extensive research explored the link between cholesterol and viral infections. In general, cholesterol in the cell membrane plays an important role when a virus enters the host cell,43 and the efficiency of viral infection is significantly reduced when cholesterol deficiency is induced in the cell membrane.44 After a viral infection has already occurred, increased levels of LDL cholesterol itself can interact with macrophages in atherosclerotic plaques or engage in inflammasome activation and increase the secretion of proinflammatory cytokines.53, 54 Furthermore, low HDL cholesterol may cause dysregulation in the innate immune response, a first-line defense mechanism against COVID-19 infection.55 Lastly, LDL cholesterol or triglyceride accumulation may cause endothelial dysfunction, increasing the risk of cardiovascular complications, leading to severe outcomes.56

However, the systematic review of Zaki et al.39 presented completely different results. In their study, total cholesterol, HDL cholesterol, and LDL cholesterol levels were consistently lower in the COVID-19-infected group than in the control group, and HDL cholesterol was significantly lower in patients with a high severity of disease. Zaki et al.39 performed a systematic review of the associations of various comorbidities, such as hypertension, diabetes, high cholesterol, and cancer, with COVID-19 severity. A total of 54 articles were included, and the authors stated that 8 analyzed high cholesterol levels, but only 3 observational studies were finally included. All 3 of those studies were conducted in China.40, 41, 42 Two studies did not confirm the presence or absence of dyslipidemia from patients' medical records,40, 42 and in 1 study, the presence of dyslipidemia was described, but its relationship with severity was not investigated.41 Instead, in all studies, various lipid profiles were tested at the time of admission, and in 1 study,40 tests were performed serially at intervals of 2 days for more than 2 weeks to analyze the relationship between lipid parameters and COVID-19 severity. Among the 7 studies included in the analysis of Hariyanto and Kurniawan38 described earlier, 1 study45 specified that patients’ baseline lipid profile was analyzed. We found that higher total, LDL, and HDL cholesterol levels showed an inverse association with severe COVID-19 in our new meta-analysis. Consistently with our results, Fan et al.57 and Wei et al.58 reported similar findings from 2 small observational studies. In studies of 21 and 597 patients, patients infected with COVID-19 had lower total cholesterol and LDL cholesterol levels than healthy controls. Severe cases had lower total cholesterol, LDL cholesterol, and HDL cholesterol levels. The authors suggested that their findings may be explained by changes in cholesterol metabolism due to COVID-19 infection, changes in lipid metabolism due to hyperinflammation, leakage of LDL cholesterol due to increased vascular permeability, and accelerated lipid degradation. Changes in lipid metabolism are an early step in atherogenesis and can cause vessel injury through coagulopathy and endothelial dysfunction. Thus, the authors emphasized the role of cholesterol in vasculopathy caused by COVID-19 infection.59

Related to this topic, Zhang et al.60 reported that in a retrospective study of 13,981 patients, statin therapy (the main treatment for dyslipidemia) significantly reduced the severity and mortality of COVID-19. In an analysis of all participants' baseline characteristics, subjects with statin therapy had less dyslipidemia, defined as a LDL cholesterol level more than the upper limit of the normal range according to the criteria at each hospital, and even after propensity score matching, there was a slight statistical difference between the two groups. However, even after correcting for various risk factors including LDL cholesterol, the mortality rate within 28 days was 5.2% and 9.4% in the statin and non-statin groups, respectively, with an adjusted hazard ratio of 0.58. The possibility that these results may reflect the pleiotropic effects of statins, including their anti-inflammatory and antioxidant effects, rather than their LDL cholesterol-lowering effect itself, has attracted attention. In particular, protease inhibitor-based antiretroviral and immunosuppressive drugs are used to treat COVID-19,61 and these drugs may exacerbate hyperlipidemia, so statins may be particularly effective in patients receiving these medications.62 Furthermore, in a study in which proteomic analysis was performed on various tissues obtained from autopsy samples of patients who died from COVID-19,63 Niemann-Pick C1 (NPC1) was significantly upregulated in most organs, including the lung, spleen, and heart. Considering that lipids and lipid metabolism play an important role in the process of viral replication,64 NPC1 may be a potential drug target for COVID-19. Prospective randomized clinical studies are needed to obtain an accurate answer.

An important limitation of this overview is that the number of studies included—reflecting the number of reviews that included data regarding the association between dyslipidemia and COVID-19 infection—was limited, precluding a stringent analysis of this end point. Moreover, the methodological quality assessment showed that both reviews had multiple critical flaws, making the current umbrella review limited. The situation regarding the COVID-19 pandemic is changing so rapidly, with such serious consequences, that numerous reports are published without a sufficient evaluation of the data quality. This may explain the low methodological quality of the reviews included in the present study. Consequently, we conducted this overview as a narrative synthesis of the evidence. In addition, we only analyzed articles in English. If the search had been done in other languages, more studies could have been included. Despite these limitations, however, this is the first umbrella review investigating the association between dyslipidemia and COVID-19 infection. Furthermore, we applied a rigorous methodology to conduct an umbrella review of systematic reviews. Hence, the evidence from this study is important from the perspective of aggressive treatment and disease prevention.

In conclusion, we conducted an umbrella review to identify the findings and contents of systematic reviews and/or meta-analyses of the relationship between dyslipidemia and COVID-19 infection severity. According to the AMSTAR 2 criteria and GRADE system, the studies did not show high quality, and the primary evidence quality of both the observational studies and the systematic reviews was considered low. Although it is difficult to draw a definitive conclusion, patients with a history of dyslipidemia are likely to be at risk for severe COVID-19 infections, but the contrary finding was shown for cholesterol levels at hospitalization. These findings suggest that dyslipidemia may potentially play a role in the severity of COVID-19 infection. These results provide clinically valuable evidence in this pandemic situation because existing research on dyslipidemia and COVID-19 is limited. More adequately powered studies are needed to obtain reliable results on this issue. It is very important to ensure that future research is well-designed, since conflicting results may occur depending on when dyslipidemia is defined or laboratory tests are performed.